Citizens Maintains Market Outperform on Structure Therapeutics, Raises Price Target to $120

Benzinga · 1d ago
Citizens analyst Jonathan Wolleben maintains Structure Therapeutics (NASDAQ:GPCR) with a Market Outperform and raises the price target from $87 to $120.